Skip to main content
Premium Trial:

Request an Annual Quote

Zetta Genomics Raises £2.5M in Seed Funding

NEW YORK — Zetta Genomics said on Tuesday that it has raised £2.5 million ($3.4 million) in seed funding.

The financing was led by Nina Capital with participation from Cambridge Enterprise and Apex Ventures.

Zetta, a spinout of the University of Cambridge, has developed a platform — called XetaBase — for the storage, management, and interrogation of large-scale genotypic and clinical data for precision medicine applications.

The UK-based company said it will use the seed money to expand its partnership network, open offices in Spain and the US, and increase its headcount in the areas of software, R&D, and product commercialization.

"Zetta Genomics re-imagines data to deliver a dynamic platform fit for the fast-emerging, fast-scaling, multi-petabyte environment," Zetta founder Ignacio Medina said in a statement. "In liberating genomic data, placing its power into the hands of researchers and clinicians, we will drive precision medicine's transformation into mainstream healthcare and life-changing patient benefit."

In mid-2020, Zetta began working with Genomics England and Sano Genetics to develop a software tool that will allow genomics research project participants with rare diseases to better self-report information and receive updates.

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.